Data bolsters long-term efficacy of Genentech's Vabysmo for macular degeneration
Marcelo Ricardo Daros


Data from two trials demonstrated the long-term efficacy and durability of Roche's (OTCQX:RHHBY) Genentech unit's Vabysmo (faricimab-svoa) for wet age-related macular degeneration.
Roche touted the potential advantages of Vabysmo over Regeneron's (NASDAQ:REGN) Eylea (aflibercept).
Over two years, results showed that greater than 60% of those receiving Vabysmo could be treated every four months while achieving comparable vision gains versus Eylea given every two months.

Also, Vabysmo patients had a median number of 10 injections compared to 15 injections for Eylea patients.
Similar reductions in central subfield thickness were observed with Vabysmo given up to every four months versus Eylea given every two.
Read why Seeking Alpha contributor Marco Lysek recently called Roche (OTCQX:RHHBY) undervalued.